Investigational drug · Phase 3
Tucidinostat
Also called: Chidamide, HBI-8000, SHR2554 analog, CS055
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
275
Any phase or sponsor naming "Tucidinostat"
First trial start
2021
Apr 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tucidinostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
- Unresectable or Metastatic Melanoma
- Progressive Brain Metastasis
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Lymphoma, T-Cell, Peripheral
- Relapsed or Refractory Peripheral T-cell Lymphoma
- Peripheral T-cell Lymphoma
- Colorectal Cancer
- Peripheral T Cell Lymphoma
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Tucidinostat" as an intervention, largest first.
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLPivotal-lookingNot yet recruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06516978 · 528 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2028
Drug: Polatuzumab vedotin; Rituximab and 9 more · For: Diffuse Large B Cell Lymphoma
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsPivotal-lookingRecruiting
Chipscreen Biosciences, Ltd.Industry
NCT06497985 · 430 participants (planned) · Start Dec 6, 2024 · Primary completion May 31, 2028
Drug: Tucidinostat; Sintilimab and 2 more · For: Colorectal Cancer
Sites: Guangzhou, China
- Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCLPivotal-lookingCompleted
Chipscreen Biosciences, Ltd.Industry
NCT04231448 · 423 participants · Start May 21, 2020 · Primary completion Jan 10, 2023
Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone); Tucidinostat and 1 more · For: Diffuse Large B-cell Lymphoma
Sites: Beijing, China; Shanghai, China
Guangdong Association of Clinical TrialsAcademic, hospital or other
NCT03574402 · 400 participants (planned) · Start Jul 9, 2018 · Primary completion Dec 30, 2022
Drug: Avitinib Maleate; Afatinib and 13 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Guangzhou, China
Ruijin HospitalAcademic, hospital or other
NCT06779435 · 400 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2027
Drug: Low intensity treatment options; Conventional immunochemotherapy regimen · For: DLBCL
Sites: Shanghai, China
- Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerPivotal-lookingCompleted
Chipscreen Biosciences, Ltd.Industry
NCT02482753 · 365 participants · Start Jul 2015 · Primary completion Mar 2018
Drug: Chidamide; exemestane and 1 more · For: Breast Cancer
Sites: Hefei, China; Beijing, China; Guangzhou, China · 22 sites in all
- ChiCGB vs BEAM in High-risk or R/R LymphomasPivotal-lookingStatus unknown
Sichuan UniversityAcademic, hospital or other
NCT05466318 · 306 participants (planned) · Start Jul 1, 2022 · Primary completion Dec 30, 2025
Drug: Chidamide; Cladribine and 6 more · For: Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell
Sites: Deyang, China; Chengdu, China; Dazhou, China · 11 sites in all
Tianjin Medical University Second HospitalAcademic, hospital or other
NCT06739395 · 300 participants (planned) · Start Nov 1, 2024 · Primary completion Dec 31, 2026
Drug: Olaparib tablet; Temozolomide capsule and 12 more · For: Solid Tumor; Precision Medicine
Sites: Tianjin, China
- Genotype-guided Treatment in Newly Diagnosed PTCLPivotal-lookingRecruiting
Ruijin HospitalAcademic, hospital or other
NCT05675813 · 264 participants (planned) · Start Feb 13, 2023 · Primary completion Jul 15, 2026
Drug: CHOP+selinexor+5-Azacitidine; CHOP+duvelisib+5-Azacitidine and 2 more · For: Peripheral T Cell Lymphoma
Sites: Shanghai, China
- Efficacy and Safety of Chidamide in CBF LeukemiaPivotal-lookingActive, not recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT03031262 · 250 participants (planned) · Start Feb 8, 2017 · Primary completion Apr 10, 2025
Drug: Cytarabine; Chidamide · For: AML
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- A single arm phase II trial of chidamide plus cisplatin in advanced adenoid cystic carcinoma.
Liu Y, Chen GL, Xue K, et al. · iScience 2026
- From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs.
Penteado AB, Hassanie H, Sousa GHM, et al. · Eur J Med Chem 2026
- Early Chidamide Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Myeloid Malignancies: A Prospective Cohort With Time-Dependent External-Control Analysis.
Yang H, Liang Q, Liu Z, et al. · Int J Cancer 2026
- Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China.
Jin Y, Zhong B, Fu J, et al. · BMJ Open 2026
- Correction to "Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase Ib Trial".
· MedComm (2020) 2026
- Histone deacetylase inhibitors as venetoclax-sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives.
Lee J, Diederich M · Br J Pharmacol 2026
Also in development for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.